ANKRD18A and liver cancer: Considering the above findings, the upregulation of Pim-3 which is driven predominantly by a low miR-936 level, can activate the ANKRD18A/Src/NRF2 pathway, probably in turn enhancing NRF2 transcriptional activity and causing sorafenib resistance in liver cancer.